Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lactobacillus reuteri ADR-1 + lactobacillus rhamnosus GM-020
- Development stage
- Unknown
- Lead developer
- Bio-Resource
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
This probiotic combination consists of two specific bacterial strains: *Lactobacillus reuteri* ADR-1 and *Lactobacillus rhamnosus* GM-020. Developed by Bio-Resource Inc., the combination is primarily investigated for its therapeutic potential in oral health and metabolic disorders. In oral health, it is used to treat chronic periodontitis by competitively inhibiting the growth of pathogens such as *Porphyromonas gingivalis* and reducing local inflammation. In metabolic health, the strains have demonstrated the ability to improve glycemic control in type 2 diabetes and reduce body fat in obesity through immunomodulatory effects and the regulation of pro-inflammatory cytokines like TNF and IL-6. The *L. reuteri* ADR-1 strain is frequently utilized in a heat-killed (paraprobiotic) form, while *L. rhamnosus* GM-020 is typically administered as a live probiotic.
- Other names
- L. reuteri ADR-1 + L. rhamnosus GM-020Limosilactobacillus reuteri ADR-1 + Lacticaseibacillus rhamnosus GM-020
02
Targets
TNFA (Tumor necrosis factor alpha (soluble))IL-6 (Interleukin 6)
Beyond the preview
Go deeper on lactobacillus reuteri ADR-1 + lactobacillus rhamnosus GM-020.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lactobacillus reuteri ADR-1 + lactobacillus rhamnosus GM-020.